Characterize rs70991108 Polymorphism of DHFR Gene

DHFR 19 bp Deletion Polymorphism and Folic Acid Utilization

DHFR mRNA and protein abundance determined for the 19 bp deletion genotypes

Effect of DHFR 19bp deletion on reactions of folate pathway determined in cell culture conditions

Tufts University

Oxaliplatin 85 mg/m2 in 2 hours intravenous infusion, + S-leucovorin 200 mg/m2, + 5-FU 2,400 mg/m2 as a 46 hours continuous infusion. The cycles are repeated every 2 weeks for a total of 8 cycle, if tumor response is stable disease, partial or complete response, then maintenance with Capecitabine 1,000 mg twice a day will be administered until disease progression, unacceptable toxicity or treatment refusal by the patient.

Metastatic Gastric Cancer

Oxaliplatin 85 mg/m2 is given as a 2 hours intravenous infusion, concomitant to and S-leucovorin 200 mg/m2, and followed by 5-FU 2,400 mg/m2 as a 46 hours continuous infusion.

FOLFOX

Capecitabine 1,000 mg twice a day will be administered until disease progression, unacceptable toxicity or treatment refusal by the patient.

Capecitabine

International group of endovascular oncology (IGEVO) website

Azienda Ospedaliera Ospedali Riuniti Marche Nord, Presidio Ospedaliero San Salvatore

Azienda Ospedaliera Ospedali Riuniti Marche Nord, Presidio San Salvatore,

Modified Folinic Acid-Fluorouracil-Oxaliplatin Regimen + Capecitabine for Elderly With Metastatic Gastric Cancer

Modified Folinic Acid-Fluorouracil-Oxaliplatin (FOLFOX) Followed by Capecitabine as First-line Chemotherapy for Elderly or Frail Patients With Metastatic or Recurrent Gastric Cancer

folinic acid/krūties vėžys

DHFR 19 bp Deletion Polymorphism and Folic Acid Utilization

Modified Folinic Acid-Fluorouracil-Oxaliplatin Regimen + Capecitabine for Elderly With Metastatic Gastric Cancer

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu